Advanced search
Publication Cover
Modern Rheumatology Volume 22, 2012 - Issue 3
Journal homepage
349
Views
64
CrossRef citations to date
0
Altmetric
Original Article

Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial

Nobuyuki MiyasakaDepartment of Medicine and Rheumatology, Graduate School, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, JapanCorrespondence[email protected]
,
Masako HaraInstitute of Rheumatology, Tokyo Women’s Medical University, 10-22 Kawadacho, Shinjuku-ku, Tokyo 162-0054, Japan
,
Takao KoikeDepartment of Medicine II, Graduate School of Medicine, Hokkaido University, N15W7 Kita-ku, Sapporo 060-8638, Japan
,
Eizo SaitoFourth Department of Internal Medicine, Toho University School of Medicine, 2-17-6 Ohashi, Meguro-ku, Tokyo 153-8515, Japan
,
Masahito YamadaDepartment of Neurology and Neurobiology of Aging, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa 920-8641, Japan
,
Yoshiya TanakaFirst Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan
& Additional Members of the GB-0998 Study Group show all
Pages 382-393 | Received 13 Jul 2011, Accepted 05 Sep 2011, Published online: 02 Jan 2014

References

  • Bradley WG. Polymyositis. Br J Hosp Med. 1977;17:351–5.
  • Cherin P. Recognition and management of myositis. Drugs. 1997;54:39–49.
  • Bohan A, Peter JB. Polymyositis and dermatomyositis. N Engl J Med. 1975;292:344–7.
  • Hara M, Kinoshita M, Saito E, Hashimoto H, Miyasaka N, Yoshida T, et al. Prospective study of high-dose intravenous immunoglobulin for the treatment of steroid-resistant polymyo-sitis and dermatomyositis. Mod Rheumatol. 2003;13:319–25.
  • Saito E, Koike T, Hashimoto H, Miyasaka N, Ikeda Y, Hara M, et al. Efficacy of high-dose intravenous immunoglobulin therapy in Japanese patients with steroid-resistant polymyositis and der-matomyositis. Mod Rheumatol. 2008;18:34–44.
  • Dalakas MC, Ilia I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000.
  • Roifman CM, Schaffer FM, Wachsmuth SE, Murphy G, Gelfand EW. Reversal of chronic polymyositis following intravenous immune serum globulin therapy. JAMA. 1987;258:513–5.
  • Dalakas MC. Polymyositis, dermatomyositis, and inclusion body myositis. In: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson JL, et al., editors. Harrison's principles of internal medicine. 17th ed. New York: McGraw-Hill; 2008. p. 2696–703.
  • Aberer W, Bagot M, Braathen L, Chimenti S, Diaz-Perez JL, Hegyi V, et al. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. European dermatology forum. Available at: http://www.euroderm.org/edf/images/stories/guide fines/guideline_on_ivig-aktuell-neu-2008.pdf. Cited 9 March 2010.
  • EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases/EFNS task force on the use of intravenous immunoglobulin in treatment of neurological dis-eases. Eur J Neurol. 2008;15:893–908.
  • Maugars YM, Berthelot JM, Abbas AA, Mussini JM, Nguyen JM, Prost AM. Long-term prognosis of 69 patients with dermato-myositis or polymyositis. Cfin Exp Rheumatol. 1996;14:263–74.
  • Marie I, Hachulla E, Hatron PY, Hellot MF, Levesque H, Devulder B, et al. Polymyositis and dermatomyositis:short term and longterm outcome, and predictive factors of prognosis. J Rheumatol. 2001;28:2230–7.
  • Oh TH, Brumfield KA, Hoskin TL, Stolp KA, Murray JA, Bassford JR. Dysphagia in inflammatory myopathy:clinical characteristics, treatment strategies, and outcome in 62 patients. Mayo Clin Proc. 2007;82:441–7.
  • Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction com-plicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology. 1992;42:257–8.
  • Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurol-ogy. 1994;44:223–6.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.